Reviewer's report

Title: Linking the Effect of Psoriatic Arthritis-Related Foot Involvement to the Leeds Foot Impact Scale using the International Classification for Functioning, Disability and Health: A Study to Assess Content Validity.

Version: 0 Date: 14 Jul 2020

Reviewer: Aimie Patience

Reviewer's report:

Thank you to the authors and editorial team for the opportunity to review this excellent paper. As the authors noted, PsA-related foot disease in an under-researched area of rheumatology practice and our clinical guidelines and management strategies are often based on the RA model of foot disease which may not take into account the cutaneous, nail and enthesal pathology that can be present in PsA-related foot disease. This paper follows on really nicely from the recently published 'Linking the Patient Experience of Foot Involvement Related to Psoriatic Arthritis to the International Classification of Functioning' paper which highlighted the significant burden of PsA-related foot disease on a wide range of aspects relating to daily life and functioning.

I have provided my point-by-point responses below which cover only minor recommendations.

*Page 2, line 26: perhaps change "the foot with psoriatic arthritis" to "the foot in psoriatic arthritis"
*Page 2, line 38: add "the" before LFIS-RA
*Page 4, line 28: remove the dash after "disease"
*Page 4, line 40: although mentioned in the discussion it could be worth noting the LFIS-RA content validity was assessed by postal survey
*Page 7, line 57: change "a slight agreement" to "as slight agreement"
*Page 8, line 21: change "linked to aspect of" to "linked to aspects of"
*Page 12, line 38: remove capital I from "Instability"
*Page 14, line 43: great point regarding the generalisability of the two different study populations. Also worth noting there will be differences in foot care provision for people with PsA-related foot disease in other countries (other than UK, Australia and New Zealand).
*Page 15, line 17: apostrophe in "patients' concerns"
*Page 15, line 38: change "PSA" to "PsA"
*Page 16, line 14: add commas to "with interest in, and knowledge of, the ICF"
*Page 16, conclusion: just for clarification - are you recommending adapting the LFIS-RA using the ICF features relevant to PsA to develop a new PsA foot-specific outcome measure? Or developing a new PsA foot-specific outcome measure using only the ICF?
*Page 29, line 37: change "here's" to "there's"

Publons Reviewer Recognition. Springer Nature can send verification of this review directly to Publons (a subsidiary of Clarivate Analytics). If you would like to take advantage of this service,
please click on the “Yes” option below. Your name, email address, title of the reviewed manuscript, name of the journal, and date of your review submission (the “Review Data”) will then be transmitted to Publons upon publication of the manuscript. If you have already registered at Publons, they will notify you of the receipt of this review and update your profile as per your settings and their policy. If you are not registered with Publons, you will receive an email from them asking you to register in order for them to be able to recognize your review on your new profile page. Publons may use the Review Data to generate derivative metadata for the benefit of Publons and you as a reviewer, carefully considering the sensitivity of such information. For example, Publons may verify your record as a reviewer by updating your profile published on its webservice if you have registered for such service or help editors to identify candidate reviewers. Please find the details of processing in Publons’ privacy policy https://publons.com/about/terms

No

**Level of interest**
Please indicate how interesting you found the manuscript:

An article of importance in its field

**Quality of written English**
Please indicate the quality of language in the manuscript:

Acceptable

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.
I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal